{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pachon-Pena G"],"funding":["Ministerio de Salud Carlos III","Spanish Ministry of Economy and Competitiveness-European Regional Development Fund","“Miguel Servet” tenure track program","Fondo de Investigacio&apos;n Sanitaria","Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders","NHLBI NIH HHS","National Institutes of Health National Heart Lung Blood Institute","ERDF"],"pagination":["1080-1092"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5367967"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(4)"],"pubmed_abstract":["The clinical effectiveness of systemically administered human mesenchymal stem cells (hMSCs) depends on their capacity to engage vascular endothelium. hMSCs derived from bone marrow (BM-hMSCs) natively lack endothelial binding capacity, but express a CD44 glycovariant containing N-linked sialyllactosamines that can be α(1,3)-fucosylated using fucosyltransferase-VI (FTVI) to enforce sLe<sup>X</sup> decorations, thereby creating hematopoietic cell E-/L-selectin ligand (HCELL). HCELL expression programs potent shear-resistant adhesion of circulating cells to endothelial beds expressing E-selectin. An alternative source of hMSCs is adipose tissue (A-hMSCs), and we assessed whether A-hMSCs bind E-selectin and/or possess sialyllactosamine-decorated CD44 accessible to α(1,3)-fucosylation. Similar"],"journal":["Stem cells (Dayton, Ohio)"],"pubmed_title":["A Glycovariant of Human CD44 is Characteristically Expressed on Human Mesenchymal Stem Cells."],"pmcid":["PMC5367967"],"funding_grant_id":["CB07708/0012","P01 HL107146","PI14/00228","PI11/0085","CP10/00438","CD10/00285","SAF2012-36186","NHLBI grant PO1 HL107146","SAF2015-65019-R"],"pubmed_authors":["Pachon-Pena G","Vendrell J","Katz A","Fernandez-Veledo S","Sackstein R","Donnelly C","Ruiz-Canada C"],"additional_accession":[]},"is_claimable":false,"name":"A Glycovariant of Human CD44 is Characteristically Expressed on Human Mesenchymal Stem Cells.","description":"The clinical effectiveness of systemically administered human mesenchymal stem cells (hMSCs) depends on their capacity to engage vascular endothelium. hMSCs derived from bone marrow (BM-hMSCs) natively lack endothelial binding capacity, but express a CD44 glycovariant containing N-linked sialyllactosamines that can be α(1,3)-fucosylated using fucosyltransferase-VI (FTVI) to enforce sLe<sup>X</sup> decorations, thereby creating hematopoietic cell E-/L-selectin ligand (HCELL). HCELL expression programs potent shear-resistant adhesion of circulating cells to endothelial beds expressing E-selectin. An alternative source of hMSCs is adipose tissue (A-hMSCs), and we assessed whether A-hMSCs bind E-selectin and/or possess sialyllactosamine-decorated CD44 accessible to α(1,3)-fucosylation. Similar","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Apr","modification":"2025-04-04T02:12:07.773Z","creation":"2019-03-26T23:22:10Z"},"accession":"S-EPMC5367967","cross_references":{"pubmed":["27888602"],"doi":["10.1002/stem.2549"]}}